The Technical AnalystExchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - General
Bristol-Myers Squibb Co Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.31% $48.99
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 99 291 mill |
| EPS: | 3.86 |
| P/E: | 12.69 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 2 026.76 mill |
| Avg Daily Volume: | 15.53 mill |
| RATING 2024-04-23 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.82x |
| Company: PE 12.69 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.26x |
| Company: PE 12.69 | industry: PE 48.81 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 47.97 - 50.01 ( +/- 2.09%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Shanahan Karin | Sell | 3 306 | Restricted Stock Units |
| 2024-04-01 | Shanahan Karin | Buy | 3 306 | Common Stock, $0.10 par value |
| 2024-04-01 | Shanahan Karin | Sell | 1 196 | Common Stock, $0.10 par value |
| 2024-03-31 | Yale Phyllis R | Buy | 645 | Deferred Share Units |
| 2024-03-31 | Storch Gerald L | Buy | 691 | Deferred Share Units |
| INSIDER POWER |
|---|
| 31.44 |
| Last 100 transactions |
| Buy: 432 337 | Sell: 225 479 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $48.99 (-0.31% ) |
| Volume | 7.07 mill |
| Avg. Vol. | 15.53 mill |
| % of Avg. Vol | 45.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BMY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Latest Press Releases
Latest News
